Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Gastrointestinal Microbiome | 12 | 2024 | 181 | 4.830 |
Why?
|
Colorectal Neoplasms | 18 | 2024 | 112 | 4.320 |
Why?
|
Circadian Rhythm | 9 | 2021 | 298 | 3.890 |
Why?
|
Microbiota | 5 | 2024 | 104 | 2.900 |
Why?
|
Colon | 9 | 2021 | 142 | 2.430 |
Why?
|
Pancreatic Neoplasms | 4 | 2022 | 97 | 2.410 |
Why?
|
Ethanol | 7 | 2022 | 120 | 2.090 |
Why?
|
Metabolic Syndrome | 3 | 2023 | 62 | 2.080 |
Why?
|
Obesity | 6 | 2023 | 321 | 2.040 |
Why?
|
Colonic Neoplasms | 6 | 2024 | 61 | 1.790 |
Why?
|
Pancreas | 3 | 2023 | 33 | 1.700 |
Why?
|
Inflammation | 7 | 2023 | 284 | 1.660 |
Why?
|
Carcinogenesis | 5 | 2019 | 25 | 1.530 |
Why?
|
Colonic Polyps | 5 | 2019 | 34 | 1.400 |
Why?
|
Coronavirus Infections | 3 | 2020 | 90 | 1.360 |
Why?
|
Pneumonia, Viral | 3 | 2020 | 94 | 1.360 |
Why?
|
Betacoronavirus | 3 | 2020 | 77 | 1.320 |
Why?
|
Colonoscopy | 9 | 2021 | 73 | 1.290 |
Why?
|
Alcoholism | 4 | 2022 | 74 | 1.270 |
Why?
|
Animals | 14 | 2022 | 3780 | 1.160 |
Why?
|
Humans | 63 | 2024 | 28408 | 1.120 |
Why?
|
Gastrointestinal Tract | 2 | 2018 | 53 | 1.120 |
Why?
|
Mice | 10 | 2022 | 1461 | 1.020 |
Why?
|
Cell Transformation, Neoplastic | 2 | 2018 | 30 | 0.990 |
Why?
|
Alcohol Drinking | 3 | 2020 | 80 | 0.960 |
Why?
|
Dysbiosis | 3 | 2023 | 56 | 0.930 |
Why?
|
Intestinal Mucosa | 4 | 2019 | 192 | 0.920 |
Why?
|
Feeding Behavior | 4 | 2022 | 92 | 0.910 |
Why?
|
Mutation | 4 | 2018 | 353 | 0.910 |
Why?
|
Pandemics | 3 | 2020 | 260 | 0.890 |
Why?
|
Epithelial Cells | 3 | 2019 | 84 | 0.890 |
Why?
|
Asthma | 3 | 2020 | 162 | 0.840 |
Why?
|
Transcriptome | 1 | 2023 | 85 | 0.830 |
Why?
|
Adenoma | 6 | 2021 | 60 | 0.800 |
Why?
|
Receptors, Opioid, mu | 1 | 2022 | 2 | 0.790 |
Why?
|
Gastrointestinal Diseases | 1 | 2022 | 36 | 0.760 |
Why?
|
Prebiotics | 2 | 2018 | 24 | 0.750 |
Why?
|
Probiotics | 2 | 2018 | 19 | 0.750 |
Why?
|
Morphine | 1 | 2022 | 61 | 0.750 |
Why?
|
Analgesics, Opioid | 2 | 2022 | 216 | 0.750 |
Why?
|
Photoperiod | 3 | 2021 | 49 | 0.740 |
Why?
|
Animal Husbandry | 1 | 2020 | 8 | 0.720 |
Why?
|
Lipase | 1 | 2020 | 4 | 0.700 |
Why?
|
Male | 36 | 2022 | 15273 | 0.700 |
Why?
|
Weight Gain | 1 | 2020 | 66 | 0.690 |
Why?
|
Time Factors | 9 | 2020 | 1490 | 0.680 |
Why?
|
Eating | 1 | 2020 | 59 | 0.670 |
Why?
|
Intestines | 3 | 2021 | 99 | 0.670 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 2 | 2023 | 21 | 0.660 |
Why?
|
Xeroderma Pigmentosum Group A Protein | 1 | 2019 | 3 | 0.660 |
Why?
|
Central Nervous System Depressants | 1 | 2019 | 20 | 0.650 |
Why?
|
Intubation, Intratracheal | 1 | 2020 | 99 | 0.620 |
Why?
|
Mice, Inbred C57BL | 5 | 2021 | 435 | 0.620 |
Why?
|
Insulin Resistance | 1 | 2018 | 52 | 0.610 |
Why?
|
Antineoplastic Agents, Immunological | 1 | 2018 | 17 | 0.600 |
Why?
|
Sleep | 1 | 2021 | 355 | 0.590 |
Why?
|
Macrophages | 1 | 2018 | 108 | 0.580 |
Why?
|
Neoplasms | 1 | 2020 | 239 | 0.580 |
Why?
|
Intestinal Diseases | 1 | 2017 | 9 | 0.550 |
Why?
|
Digestive System Diseases | 1 | 2016 | 5 | 0.530 |
Why?
|
Serpins | 1 | 2016 | 4 | 0.530 |
Why?
|
Eye Proteins | 1 | 2016 | 6 | 0.530 |
Why?
|
Female | 31 | 2021 | 15708 | 0.520 |
Why?
|
Adenocarcinoma | 2 | 2015 | 147 | 0.510 |
Why?
|
Nerve Growth Factors | 1 | 2016 | 37 | 0.510 |
Why?
|
Interleukin-17 | 1 | 2015 | 18 | 0.500 |
Why?
|
Mass Screening | 5 | 2017 | 182 | 0.500 |
Why?
|
Multiple Organ Failure | 2 | 2012 | 21 | 0.490 |
Why?
|
Pancreatitis | 2 | 2012 | 20 | 0.490 |
Why?
|
Genetic Predisposition to Disease | 6 | 2017 | 390 | 0.480 |
Why?
|
Biopsy | 2 | 2021 | 220 | 0.470 |
Why?
|
Diet | 3 | 2023 | 220 | 0.460 |
Why?
|
Medicine, Arabic | 1 | 2014 | 1 | 0.460 |
Why?
|
Hepatic Artery | 1 | 2014 | 3 | 0.450 |
Why?
|
Middle Aged | 22 | 2024 | 9254 | 0.450 |
Why?
|
Gastrointestinal Hemorrhage | 1 | 2014 | 20 | 0.450 |
Why?
|
Infarction | 1 | 2014 | 30 | 0.450 |
Why?
|
Sarcoidosis | 1 | 2014 | 14 | 0.440 |
Why?
|
Liver Diseases | 1 | 2014 | 35 | 0.430 |
Why?
|
Risk Factors | 7 | 2022 | 2408 | 0.430 |
Why?
|
Adult | 23 | 2022 | 8097 | 0.410 |
Why?
|
Feces | 3 | 2024 | 108 | 0.410 |
Why?
|
Liver | 1 | 2014 | 160 | 0.410 |
Why?
|
Inflammation Mediators | 1 | 2012 | 68 | 0.380 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2012 | 192 | 0.360 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2012 | 284 | 0.360 |
Why?
|
Genes, ras | 2 | 2008 | 13 | 0.340 |
Why?
|
Microsatellite Instability | 2 | 2008 | 9 | 0.340 |
Why?
|
Iran | 11 | 2017 | 32 | 0.320 |
Why?
|
Biomarkers | 3 | 2020 | 596 | 0.320 |
Why?
|
Incidence | 4 | 2021 | 773 | 0.310 |
Why?
|
Aged | 18 | 2021 | 9262 | 0.300 |
Why?
|
Food Hypersensitivity | 2 | 2020 | 40 | 0.300 |
Why?
|
Rhinitis, Allergic | 2 | 2020 | 16 | 0.300 |
Why?
|
Early Detection of Cancer | 4 | 2017 | 104 | 0.300 |
Why?
|
Body Mass Index | 2 | 2021 | 465 | 0.300 |
Why?
|
Comorbidity | 3 | 2022 | 500 | 0.300 |
Why?
|
Inflammatory Bowel Diseases | 2 | 2023 | 88 | 0.280 |
Why?
|
Phenotype | 2 | 2021 | 311 | 0.280 |
Why?
|
Prospective Studies | 7 | 2023 | 1805 | 0.280 |
Why?
|
Sinusitis | 2 | 2020 | 161 | 0.260 |
Why?
|
Esophageal Achalasia | 4 | 2006 | 18 | 0.250 |
Why?
|
NF-kappa B | 2 | 2022 | 118 | 0.240 |
Why?
|
Severity of Illness Index | 3 | 2020 | 986 | 0.240 |
Why?
|
Age Factors | 6 | 2020 | 781 | 0.240 |
Why?
|
Cross-Sectional Studies | 4 | 2022 | 932 | 0.230 |
Why?
|
United States | 2 | 2021 | 2197 | 0.220 |
Why?
|
Sex Factors | 4 | 2020 | 475 | 0.220 |
Why?
|
Bicycling | 1 | 2023 | 3 | 0.220 |
Why?
|
Fibroblasts | 1 | 2023 | 59 | 0.220 |
Why?
|
Pilot Projects | 6 | 2023 | 439 | 0.220 |
Why?
|
Cadherins | 2 | 2020 | 36 | 0.210 |
Why?
|
Period Circadian Proteins | 2 | 2021 | 22 | 0.210 |
Why?
|
Cohort Studies | 5 | 2020 | 1926 | 0.210 |
Why?
|
Cytomegalovirus Infections | 1 | 2023 | 35 | 0.210 |
Why?
|
Mercaptopurine | 1 | 2023 | 4 | 0.210 |
Why?
|
Colorectal Neoplasms, Hereditary Nonpolyposis | 2 | 2017 | 11 | 0.200 |
Why?
|
Receptors, G-Protein-Coupled | 2 | 2019 | 30 | 0.200 |
Why?
|
beta-Glucans | 1 | 2022 | 24 | 0.200 |
Why?
|
Databases, Factual | 2 | 2021 | 358 | 0.200 |
Why?
|
Cell-Derived Microparticles | 1 | 2022 | 8 | 0.200 |
Why?
|
Catheterization | 4 | 2006 | 45 | 0.200 |
Why?
|
Long Interspersed Nucleotide Elements | 1 | 2021 | 5 | 0.190 |
Why?
|
Cell Line | 1 | 2022 | 280 | 0.190 |
Why?
|
Carcinoma | 2 | 2016 | 69 | 0.180 |
Why?
|
Circadian Clocks | 1 | 2021 | 32 | 0.180 |
Why?
|
Leptin | 1 | 2020 | 22 | 0.180 |
Why?
|
Eczema | 1 | 2020 | 3 | 0.180 |
Why?
|
Food | 1 | 2020 | 34 | 0.180 |
Why?
|
Glucose | 1 | 2020 | 55 | 0.180 |
Why?
|
Random Allocation | 1 | 2020 | 129 | 0.180 |
Why?
|
Cell Line, Tumor | 2 | 2018 | 249 | 0.170 |
Why?
|
Symptom Assessment | 1 | 2020 | 20 | 0.170 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2022 | 177 | 0.170 |
Why?
|
Surveys and Questionnaires | 3 | 2021 | 1216 | 0.170 |
Why?
|
Insulin | 1 | 2020 | 90 | 0.170 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2022 | 191 | 0.170 |
Why?
|
Blood Glucose | 1 | 2020 | 108 | 0.170 |
Why?
|
Olfaction Disorders | 1 | 2020 | 49 | 0.170 |
Why?
|
Immunity, Mucosal | 1 | 2019 | 17 | 0.170 |
Why?
|
Histone Deacetylases | 1 | 2019 | 11 | 0.170 |
Why?
|
Butyrates | 1 | 2019 | 22 | 0.170 |
Why?
|
Pemphigoid, Benign Mucous Membrane | 1 | 2019 | 4 | 0.170 |
Why?
|
DNA Methylation | 1 | 2021 | 165 | 0.170 |
Why?
|
Colitis | 1 | 2019 | 37 | 0.160 |
Why?
|
Opioid-Related Disorders | 1 | 2021 | 59 | 0.160 |
Why?
|
DNA Damage | 1 | 2019 | 28 | 0.160 |
Why?
|
Specimen Handling | 1 | 2019 | 44 | 0.160 |
Why?
|
Bacterial Physiological Phenomena | 1 | 2018 | 2 | 0.160 |
Why?
|
Nutritional Physiological Phenomena | 1 | 2018 | 6 | 0.160 |
Why?
|
Mice, Transgenic | 1 | 2019 | 225 | 0.160 |
Why?
|
Biodiversity | 1 | 2019 | 35 | 0.160 |
Why?
|
Immune System | 1 | 2018 | 15 | 0.160 |
Why?
|
Autoantibodies | 1 | 2019 | 80 | 0.160 |
Why?
|
RAW 264.7 Cells | 1 | 2018 | 3 | 0.150 |
Why?
|
Combined Modality Therapy | 2 | 2018 | 307 | 0.150 |
Why?
|
Intestinal Absorption | 1 | 2018 | 37 | 0.150 |
Why?
|
Carcinoma, Pancreatic Ductal | 1 | 2018 | 11 | 0.150 |
Why?
|
Mice, Inbred NOD | 1 | 2018 | 30 | 0.150 |
Why?
|
Costimulatory and Inhibitory T-Cell Receptors | 1 | 2018 | 3 | 0.150 |
Why?
|
Mice, SCID | 1 | 2018 | 45 | 0.150 |
Why?
|
Precancerous Conditions | 1 | 2018 | 25 | 0.150 |
Why?
|
Risk Reduction Behavior | 1 | 2018 | 46 | 0.150 |
Why?
|
Health Knowledge, Attitudes, Practice | 2 | 2017 | 185 | 0.150 |
Why?
|
Occult Blood | 1 | 2017 | 2 | 0.150 |
Why?
|
Young Adult | 3 | 2020 | 2069 | 0.150 |
Why?
|
Adolescent | 4 | 2020 | 2307 | 0.150 |
Why?
|
Organoids | 1 | 2017 | 9 | 0.150 |
Why?
|
Cell Proliferation | 1 | 2018 | 178 | 0.140 |
Why?
|
Stem Cells | 1 | 2017 | 41 | 0.140 |
Why?
|
Genetic Testing | 1 | 2017 | 59 | 0.140 |
Why?
|
Pollen | 1 | 2016 | 2 | 0.140 |
Why?
|
Eosinophilic Esophagitis | 1 | 2016 | 3 | 0.140 |
Why?
|
Mast Cells | 1 | 2016 | 18 | 0.140 |
Why?
|
Disease Models, Animal | 1 | 2019 | 619 | 0.130 |
Why?
|
Awareness | 1 | 2016 | 45 | 0.130 |
Why?
|
Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2016 | 5 | 0.130 |
Why?
|
Tumor Microenvironment | 1 | 2016 | 16 | 0.130 |
Why?
|
Treatment Outcome | 6 | 2018 | 3615 | 0.130 |
Why?
|
Fibrosis | 1 | 2016 | 30 | 0.130 |
Why?
|
Gastroesophageal Reflux | 1 | 2016 | 27 | 0.130 |
Why?
|
Ubiquitin-Protein Ligases | 1 | 2016 | 30 | 0.130 |
Why?
|
Tumor Suppressor Proteins | 1 | 2016 | 34 | 0.130 |
Why?
|
Neoplasms, Second Primary | 1 | 2016 | 40 | 0.130 |
Why?
|
Patient Acceptance of Health Care | 1 | 2016 | 81 | 0.130 |
Why?
|
Family | 1 | 2016 | 115 | 0.120 |
Why?
|
Mice, Knockout | 1 | 2016 | 316 | 0.120 |
Why?
|
Cholangitis, Sclerosing | 1 | 2015 | 3 | 0.120 |
Why?
|
Common Variable Immunodeficiency | 1 | 2015 | 4 | 0.120 |
Why?
|
Immunohistochemistry | 1 | 2015 | 362 | 0.120 |
Why?
|
Acute Disease | 2 | 2012 | 208 | 0.110 |
Why?
|
Developing Countries | 1 | 2014 | 14 | 0.110 |
Why?
|
Receptors, Cytoplasmic and Nuclear | 1 | 2014 | 28 | 0.110 |
Why?
|
Global Health | 1 | 2014 | 42 | 0.110 |
Why?
|
Abdominal Pain | 1 | 2014 | 8 | 0.110 |
Why?
|
Rhinitis | 1 | 2016 | 143 | 0.110 |
Why?
|
Aneurysm, False | 1 | 2014 | 7 | 0.110 |
Why?
|
Cholecystitis | 1 | 2014 | 10 | 0.110 |
Why?
|
Environment | 1 | 2014 | 47 | 0.110 |
Why?
|
Angiography | 1 | 2014 | 34 | 0.110 |
Why?
|
Aged, 80 and over | 3 | 2020 | 4853 | 0.110 |
Why?
|
Epigenesis, Genetic | 1 | 2014 | 86 | 0.110 |
Why?
|
Disease Progression | 1 | 2016 | 717 | 0.110 |
Why?
|
Embolization, Therapeutic | 1 | 2014 | 60 | 0.110 |
Why?
|
Life Style | 1 | 2014 | 201 | 0.100 |
Why?
|
Natural Language Processing | 1 | 2012 | 8 | 0.100 |
Why?
|
Pennsylvania | 1 | 2012 | 7 | 0.100 |
Why?
|
Insulin Receptor Substrate Proteins | 1 | 2012 | 15 | 0.100 |
Why?
|
Gene Frequency | 1 | 2012 | 63 | 0.100 |
Why?
|
Software | 1 | 2012 | 65 | 0.100 |
Why?
|
Promoter Regions, Genetic | 1 | 2012 | 96 | 0.100 |
Why?
|
Cell Differentiation | 1 | 2012 | 135 | 0.090 |
Why?
|
Electronic Health Records | 1 | 2012 | 75 | 0.090 |
Why?
|
Genotype | 1 | 2012 | 359 | 0.090 |
Why?
|
Geography | 1 | 2009 | 18 | 0.080 |
Why?
|
Genes, p53 | 1 | 2009 | 18 | 0.080 |
Why?
|
Food Supply | 1 | 2009 | 12 | 0.080 |
Why?
|
CpG Islands | 1 | 2009 | 54 | 0.080 |
Why?
|
Permeability | 2 | 2021 | 120 | 0.080 |
Why?
|
Molecular Biology | 1 | 2009 | 11 | 0.080 |
Why?
|
Caco-2 Cells | 2 | 2023 | 57 | 0.080 |
Why?
|
Retrospective Studies | 5 | 2017 | 3609 | 0.080 |
Why?
|
DNA Mutational Analysis | 1 | 2008 | 59 | 0.080 |
Why?
|
Botulinum Toxins, Type A | 2 | 2006 | 8 | 0.070 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2008 | 82 | 0.070 |
Why?
|
Anti-Dyskinesia Agents | 1 | 2006 | 1 | 0.070 |
Why?
|
Botulinum Toxins | 1 | 2006 | 8 | 0.070 |
Why?
|
Codon | 1 | 2006 | 5 | 0.070 |
Why?
|
Italy | 1 | 2006 | 11 | 0.070 |
Why?
|
Risk Assessment | 2 | 2020 | 676 | 0.060 |
Why?
|
Myocardial Infarction | 1 | 2006 | 145 | 0.060 |
Why?
|
Registries | 1 | 2005 | 188 | 0.060 |
Why?
|
Neuromuscular Agents | 1 | 2004 | 4 | 0.060 |
Why?
|
Prognosis | 2 | 2020 | 825 | 0.060 |
Why?
|
Celecoxib | 1 | 2023 | 5 | 0.050 |
Why?
|
Arachidonate 5-Lipoxygenase | 1 | 2023 | 6 | 0.050 |
Why?
|
Ganciclovir | 1 | 2023 | 8 | 0.050 |
Why?
|
Ki-67 Antigen | 1 | 2023 | 16 | 0.050 |
Why?
|
Cyclooxygenase 2 | 1 | 2023 | 28 | 0.050 |
Why?
|
Cytomegalovirus | 1 | 2023 | 15 | 0.050 |
Why?
|
ErbB Receptors | 1 | 2023 | 54 | 0.050 |
Why?
|
Thioguanine | 1 | 2023 | 4 | 0.050 |
Why?
|
Azathioprine | 1 | 2023 | 8 | 0.050 |
Why?
|
Chronotherapy | 1 | 2023 | 9 | 0.050 |
Why?
|
Quality Indicators, Health Care | 2 | 2014 | 38 | 0.050 |
Why?
|
Cross-Over Studies | 1 | 2023 | 63 | 0.050 |
Why?
|
Syk Kinase | 1 | 2022 | 10 | 0.050 |
Why?
|
Lectins, C-Type | 1 | 2022 | 46 | 0.050 |
Why?
|
Meals | 1 | 2022 | 10 | 0.050 |
Why?
|
Biology | 1 | 2022 | 8 | 0.050 |
Why?
|
Suprachiasmatic Nucleus | 1 | 2021 | 13 | 0.050 |
Why?
|
Hyperplasia | 1 | 2021 | 20 | 0.050 |
Why?
|
Luciferases | 1 | 2021 | 25 | 0.050 |
Why?
|
Apoptosis | 1 | 2022 | 205 | 0.050 |
Why?
|
Observer Variation | 1 | 2021 | 102 | 0.040 |
Why?
|
Boston | 1 | 2020 | 27 | 0.040 |
Why?
|
Congresses as Topic | 1 | 2020 | 31 | 0.040 |
Why?
|
Signal Transduction | 1 | 2022 | 447 | 0.040 |
Why?
|
Mucous Membrane | 1 | 2019 | 29 | 0.040 |
Why?
|
Freezing | 1 | 2019 | 13 | 0.040 |
Why?
|
RNA, Ribosomal, 16S | 1 | 2019 | 55 | 0.040 |
Why?
|
Bacteria | 1 | 2019 | 74 | 0.040 |
Why?
|
Proof of Concept Study | 1 | 2018 | 12 | 0.040 |
Why?
|
Motor Activity | 1 | 2021 | 329 | 0.040 |
Why?
|
Reproducibility of Results | 1 | 2021 | 735 | 0.040 |
Why?
|
Reagent Kits, Diagnostic | 1 | 2017 | 7 | 0.040 |
Why?
|
Transcription Factor HES-1 | 1 | 2017 | 4 | 0.040 |
Why?
|
Keratin-20 | 1 | 2017 | 4 | 0.040 |
Why?
|
Jejunum | 1 | 2017 | 12 | 0.040 |
Why?
|
Receptor, Notch1 | 1 | 2017 | 6 | 0.040 |
Why?
|
Chromogranin A | 1 | 2017 | 10 | 0.040 |
Why?
|
Occludin | 1 | 2017 | 11 | 0.040 |
Why?
|
Cell Lineage | 1 | 2017 | 24 | 0.040 |
Why?
|
Fatty Liver | 1 | 2017 | 31 | 0.040 |
Why?
|
Fatty Acids | 1 | 2017 | 41 | 0.040 |
Why?
|
Proto-Oncogene Proteins | 1 | 2017 | 35 | 0.030 |
Why?
|
Feasibility Studies | 1 | 2017 | 231 | 0.030 |
Why?
|
Syndrome | 1 | 2016 | 82 | 0.030 |
Why?
|
Protein Splicing | 1 | 2016 | 1 | 0.030 |
Why?
|
Homologous Recombination | 1 | 2016 | 1 | 0.030 |
Why?
|
BRCA1 Protein | 1 | 2016 | 4 | 0.030 |
Why?
|
Ubiquitination | 1 | 2016 | 15 | 0.030 |
Why?
|
Population Surveillance | 1 | 2016 | 110 | 0.030 |
Why?
|
Odds Ratio | 1 | 2016 | 268 | 0.030 |
Why?
|
Injections | 2 | 2006 | 44 | 0.030 |
Why?
|
DNA-Binding Proteins | 1 | 2017 | 274 | 0.030 |
Why?
|
Immunoglobulin M | 1 | 2015 | 16 | 0.030 |
Why?
|
Alkaline Phosphatase | 1 | 2015 | 19 | 0.030 |
Why?
|
Immunoglobulin A | 1 | 2015 | 13 | 0.030 |
Why?
|
Academic Medical Centers | 1 | 2016 | 137 | 0.030 |
Why?
|
Practice Guidelines as Topic | 1 | 2017 | 320 | 0.030 |
Why?
|
Aspartate Aminotransferases | 1 | 2015 | 15 | 0.030 |
Why?
|
Alanine Transaminase | 1 | 2015 | 16 | 0.030 |
Why?
|
Prevalence | 1 | 2016 | 467 | 0.030 |
Why?
|
Case-Control Studies | 1 | 2016 | 593 | 0.030 |
Why?
|
Immunoglobulin G | 1 | 2015 | 94 | 0.030 |
Why?
|
Chronic Disease | 1 | 2016 | 441 | 0.030 |
Why?
|
Antineoplastic Agents | 1 | 2016 | 190 | 0.030 |
Why?
|
Recurrence | 2 | 2006 | 322 | 0.030 |
Why?
|
Cell Polarity | 1 | 2012 | 5 | 0.030 |
Why?
|
HT29 Cells | 1 | 2012 | 8 | 0.030 |
Why?
|
Data Mining | 1 | 2012 | 4 | 0.020 |
Why?
|
Protein Transport | 1 | 2012 | 32 | 0.020 |
Why?
|
Cecum | 1 | 2012 | 12 | 0.020 |
Why?
|
Informed Consent | 1 | 2012 | 23 | 0.020 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2012 | 112 | 0.020 |
Why?
|
Follow-Up Studies | 2 | 2006 | 1858 | 0.020 |
Why?
|
Liver Neoplasms | 1 | 2012 | 105 | 0.020 |
Why?
|
Predictive Value of Tests | 1 | 2012 | 492 | 0.020 |
Why?
|
Sensitivity and Specificity | 1 | 2012 | 517 | 0.020 |
Why?
|
Cluster Analysis | 1 | 2009 | 46 | 0.020 |
Why?
|
Myocardial Reperfusion | 1 | 2006 | 5 | 0.020 |
Why?
|
Coronary Care Units | 1 | 2006 | 5 | 0.020 |
Why?
|
Angioplasty | 1 | 2006 | 6 | 0.020 |
Why?
|
Esophageal Sphincter, Lower | 1 | 2006 | 2 | 0.020 |
Why?
|
Barium | 1 | 2006 | 13 | 0.020 |
Why?
|
Manometry | 1 | 2006 | 17 | 0.020 |
Why?
|
Neurotoxins | 1 | 2006 | 16 | 0.020 |
Why?
|
Thrombolytic Therapy | 1 | 2006 | 50 | 0.020 |
Why?
|
Chest Pain | 1 | 2006 | 19 | 0.020 |
Why?
|
Electrocardiography | 1 | 2006 | 119 | 0.020 |
Why?
|
Deglutition Disorders | 1 | 2006 | 35 | 0.020 |
Why?
|
Esophagus | 1 | 2006 | 65 | 0.020 |
Why?
|
Data Interpretation, Statistical | 1 | 2006 | 83 | 0.020 |
Why?
|
Hospital Mortality | 1 | 2006 | 147 | 0.020 |
Why?
|
Age Distribution | 1 | 2005 | 89 | 0.020 |
Why?
|
Family Health | 1 | 2005 | 36 | 0.020 |
Why?
|
Age of Onset | 1 | 2005 | 99 | 0.020 |
Why?
|
Models, Statistical | 1 | 2005 | 129 | 0.010 |
Why?
|
Remission Induction | 1 | 2004 | 90 | 0.010 |
Why?
|
Endoscopy | 1 | 2006 | 182 | 0.010 |
Why?
|
Secondary Prevention | 1 | 2004 | 54 | 0.010 |
Why?
|
Equipment Design | 1 | 2004 | 152 | 0.010 |
Why?
|
Radiography | 1 | 2006 | 639 | 0.010 |
Why?
|
Child | 1 | 2004 | 1421 | 0.010 |
Why?
|